The regulatory authority of Brazil has signed off Inovio Pharmaceuticals Inc's global Phase 3 segment of its INNOVATE Phase 2/3 trial for INO-4800, DNA COVID-19 vaccine candidate.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,